Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Merck & Co (NYSE:MRK) against its key competitors in the Pharmaceuticals industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
Merck & Co Background Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Merck & Co Inc | 921.64 | 8.70 | 5.47 | -3.11% | $-0.77 | $10.72 | 5.78% |
| Eli Lilly and Co | 131.90 | 67.48 | 20.25 | 19.91% | $3.03 | $7.57 | 28.1% |
| Novo Nordisk A/S | 45.23 | 35.27 | 16.30 | 22.01% | $28.51 | $55.85 | 36.95% |
| Johnson & Johnson | 30.96 | 5.64 | 4.84 | 5.78% | $6.82 | $14.6 | 7.3% |
| Novartis AG | 25.16 | 4.52 | 4.62 | 19.99% | $4.18 | $8.75 | 7.39% |
| AstraZeneca PLC | 34.82 | 5.25 | 4.52 | 2.52% | $2.18 | $9.72 | 7.29% |
| Pfizer Inc | 72.68 | 1.71 | 2.59 | -3.62% | $-1.77 | $6.69 | -41.34% |
| Sanofi SA | 20.73 | 1.50 | 2.41 | -0.75% | $0.42 | $8.15 | 6.5% |
| Bristol-Myers Squibb Co | 13.09 | 3.47 | 2.33 | 6.03% | $4.45 | $8.73 | 0.62% |
| Zoetis Inc | 39.25 | 18.23 | 10.77 | 10.42% | $0.83 | $1.49 | 8.48% |
| GSK PLC | 13.95 | 5.08 | 2.27 | 2.64% | $1.78 | $5.63 | -1.17% |
| Takeda Pharmaceutical Co Ltd | 39.72 | 1.04 | 1.69 | -0.69% | $202.28 | $699.51 | 4.07% |
| Viatris Inc | 8.76 | 0.76 | 1.03 | 1.59% | $1.22 | $1.69 | -3.34% |
| Dr Reddy's Laboratories Ltd | 20.33 | 3.96 | 3.91 | 5.29% | $22.42 | $42.2 | 6.57% |
| Jazz Pharmaceuticals PLC | 159.39 | 2.39 | 2.43 | 4.19% | $0.33 | $0.87 | 3.35% |
| Average | 46.86 | 11.16 | 5.71 | 6.81% | $19.76 | $62.25 | 5.05% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } After examining Merck & Co, the following trends can be inferred:
- Notably, the current Price to Earnings ratio for this stock, 921.64, is 19.67x above the industry norm, reflecting a higher valuation relative to the industry.
- Considering a Price to Book ratio of 8.7, which is well below the industry average by 0.78x, the stock may be undervalued based on its book value compared to its peers.
- Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 5.47, which is 0.96x the industry average.
- With a Return on Equity (ROE) of -3.11% that is 9.92% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
- With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $-770 Million, which is -0.04x below the industry average, the company may face lower profitability or financial challenges.
- The gross profit of $10.72 Billion is 0.17x below that of its industry, suggesting potential lower revenue after accounting for production costs.
-
The company's revenue growth of 5.78% exceeds the industry average of 5.05%, indicating strong sales performance and market outperformance.
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating Merck & Co alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
- Compared to its top 4 peers, Merck & Co has a stronger financial position indicated by its lower debt-to-equity ratio of 0.93.
- This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.